Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) AI Stock Analysis

• Market Cap: HK$1.01B
• Dividend Yield: N/A
• Average Volume (3M): 2.25M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.04
• Revenue Growth: -4.88%
• EPS Growth: -34.75%
• Country: HK
• Employees: 260
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Agricultural Inputs
• EPS (TTM): N/A
• Shares Outstanding: 1,436,400,000
• 10 Day Avg. Volume: 789,500
• 30 Day Avg. Volume: 2,251,633
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$0.50
• Price Target Upside: 4.17% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: HK$0.50 ▲(4.17% Upside)

The stock's score is primarily impacted by its poor financial performance, with significant revenue decline and high leverage. The technical analysis suggests neutral market conditions, but the negative valuation metrics indicate potential overvaluation. Without earnings call insights or corporate events, these factors are the most significant in the assessment.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (8189) is a China-based company primarily engaged in the development, production, and sale of biomedical products. The company operates in the healthcare sector, focusing on the research and commercialization of innovative medical technologies and solutions. Its core products include diagnostic reagents, medical testing equipment, and other biomedical devices designed to improve healthcare outcomes.

How the Company Makes Money

Tianjin TEDA Biomedical Engineering Co. Ltd. generates revenue through the sale of its biomedical products, including diagnostic reagents and medical testing equipment, to healthcare facilities and distributors. The company may also engage in partnerships with other biomedical firms or research institutions to co-develop new technologies, which could provide additional revenue streams through licensing agreements or joint ventures. Sales and distribution agreements with hospitals, clinics, and laboratories contribute to the company's earnings, along with potential government contracts and grants for specific healthcare projects.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Financial Statement Overview

Summary

The company is facing significant financial challenges, with declining revenue, persistent losses, high leverage, and negative cash flows indicating critical financial instability. The company needs strategic restructuring to improve profitability and liquidity.

Income Statement

The income statement reveals a declining trend in revenue, with Total Revenue decreasing from 476 million in 2021 to 385 million in 2024. Gross Profit Margin has narrowed significantly, and the company has been consistently incurring net losses, with a Net Income of -27.8 million in 2024. The EBIT and EBITDA margins are negative, indicating operational inefficiencies and challenges in maintaining profitability.

Balance Sheet

The balance sheet shows a weak financial structure with a high Debt-to-Equity ratio, increasing from 0.38 in 2019 to 7.22 in 2024, indicating heavy reliance on debt financing. Stockholders' Equity has diminished substantially, impacting the Equity Ratio, which fell to 6.66% in 2024. The company’s high leverage poses significant financial risk.

Cash Flow

Cash flow analysis points to severe issues, with Operating Cash Flow consistently negative, signaling poor cash generation ability. Free Cash Flow has been negative over multiple years, showing challenges in maintaining liquidity. The lack of positive cash flow ratios suggests difficulties in converting profits into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	385.48M	398.00M	449.68M	476.38M	369.36M
Gross Profit	16.97M	21.37M	16.40M	45.60M	40.39M
EBITDA	-20.19M	4.79M	-2.26M	-29.86M	-14.65M
Net Income	-27.80M	-20.16M	-26.65M	-44.78M	-50.36M
Balance Sheet
Total Assets	332.53M	303.28M	337.20M	347.60M	392.92M
Cash, Cash Equivalents and Short-Term Investments	25.40M	5.93M	9.55M	29.78M	35.53M
Total Debt	159.92M	83.56M	96.01M	90.34M	54.65M
Total Liabilities	304.09M	238.70M	253.48M	237.24M	237.77M
Stockholders Equity	22.15M	49.95M	72.67M	100.78M	143.04M
Cash Flow
Free Cash Flow	-28.83M	-15.62M	-21.62M	-40.38M	21.96M
Operating Cash Flow	-26.27M	-13.15M	-12.82M	-6.68M	35.99M
Investing Cash Flow	-37.24M	-467.44K	-12.93M	-8.51M	-26.51M
Financing Cash Flow	82.95M	12.73M	6.17M	28.10M	-20.19M

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8189, the sentiment is Positive. The current price of 0.48 is above the 20-day moving average (MA) of 0.47, above the 50-day MA of 0.44, and above the 200-day MA of 0.40, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.91 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8189.

Tianjin TEDA Biomedical Engineering Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1866	76 Outperform	HK$9.33B	5.96	15.41%	3.78%	0.82%	2.99%
0297	76 Outperform	$10.19B	8.85	10.52%	3.94%	-4.50%	58.32%
3983	71 Outperform	$10.14B	8.73	5.83%	5.98%	-9.71%	-56.34%
8189	45 Neutral	HK$1.01B	―	-81.86%	―	-4.88%	-34.75%
Sector *	44 Neutral	C$930.37M	-8.96	-0.23%	2.69%	23.24%	-42.45%
0827	36 Underperform	HK$150.70M	―	-76.72%	―	-12.18%	-222.34%